PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge

Experimental & Molecular Medicine 2026 Open access

Read full text
Authors: Weiyun Wang, Chenghui Cai, Sisi Qin, Liujun He, Qinhao Liang, Tang Siyao, Jie Xie, Ting Long, Jing Hou, Wootae Kim, Fei Zhao
DOI: 10.1038/s12276-026-01673-8
Cited by: 8
References: 98

Abstract

Breast cancer remains the leading cause of cancer-related mortality among women worldwide. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a critical therapeutic option, particularly for patients with triple-negative breast cancer and other HER2-negative metastatic breast cancer harboring BRCA mutations. Despite their clinical success, the emergence of primary and acquired resistance to PARP inhibitors poses a significant challenge, limiting their long-term effectiveness. Here we provide a comprehensive overview of the mechanisms underlying the action of PARP inhibitors, as well as their clinical development and application. In addition, we discuss the factors driving resistance and potential strategies to overcome it in the context of PARP inhibitors.

Fields of Study & Subjects

PARP inhibition in cancer therapy Advanced Breast Cancer Therapies BRCA gene mutations in cancer

Publication details

Journal / source
Experimental & Molecular Medicine
Publisher
Springer Science and Business Media LLC
Volume
58
Issue
4
Pages
981–992
Publication date
10 April 2026
Language
EN